Helicobacter pylori infection.
Delaney
Brendan
B
Department of Primary Care and General Practice, University of Birmingham, Birmingham, UK.
Moayyedi
Paul
P
Forman
David
D
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D004942:Esophagitis, Peptic / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013274:Stomach Neoplasms / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents